Susan Quinn

1.1k total citations
14 papers, 909 citations indexed

About

Susan Quinn is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Susan Quinn has authored 14 papers receiving a total of 909 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Susan Quinn's work include Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (8 papers) and HER2/EGFR in Cancer Research (5 papers). Susan Quinn is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (8 papers) and HER2/EGFR in Cancer Research (5 papers). Susan Quinn collaborates with scholars based in United States, South Korea and Spain. Susan Quinn's co-authors include Charles Zacharchuk, Christine Powell, Thomas J. Lynch, Lecia V. Sequist, Kwok‐Kin Wong, Keith D. Eaton, Benjamin Besse, Vincent A. Miller, Amy Freyman and Revathi Ananthakrishnan and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Susan Quinn

14 papers receiving 882 citations

Peers

Countries citing papers authored by Susan Quinn

Since Specialization

Citations

This map shows the geographic impact of Susan Quinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Quinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Quinn more than expected).

Fields of papers citing papers by Susan Quinn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Quinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Quinn. The network helps show where Susan Quinn may publish in the future.

Co-authorship network of co-authors of Susan Quinn

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Quinn. A scholar is included among the top collaborators of Susan Quinn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Quinn. Susan Quinn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer 2019 ·Investigational New Drugs ·Weiwei Tan, Nagdeep Giri, Susan Quinn, Keith D. Wilner, Kourosh Parivar	5
2	Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer 2019 ·Future Oncology ·J. Corral, Tony Mok, Kazuhiko Nakagawa, Rafael Rosell, Ki Hyeong Lee, Maria Rita Migliorino, Adam Płużański, R. Linke, Geeta Devgan, Weiwei Tan, Susan Quinn, Tao Wang, Yi‐Long Wu	30
3	MA26.11 Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC 2018 ·Journal of Thoracic Oncology ·Tony Mok, Kazuhiko Nakagawa, Rafael Rosell, Kyoung Bun Lee, J. Corral, M.R. Migliorino, Adam Płużański, R. Linke, Geeta Devgan, Eric Sbar, Susan Quinn, (unknown), Yi‐Long Wu	5
4	Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers 2017 ·Lung Cancer ·Helena A. Yu, Myung‐Ju Ahn, Byoung Chul Cho, David E. Gerber, Ronald B. Natale, Mark A. Socinski, Nagdeep Giri, Susan Quinn, Eric Sbar, Hui Zhang, Giuseppe Giaccone	8
5	Potential Predictive Markers of Efficacy of Dacomitinib in Patients with Recurrent/Metastatic Scchn from a Phase 2 Trial 2013 ·Annals of Oncology ·Denis Soulières, Ghassan Allo, (unknown), (unknown), (unknown), (unknown), Susan Quinn, Ian W. Taylor, Patricia A. English, Lillian L. Siu	1
6	Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial. 2013 ·Journal of Clinical Oncology ·(unknown), Ghassan Allo, Xiaoduan Weng, Lucia Kim, (unknown), Suzanne Kamel‐Reid, Lillian L. Siu, François Coutlée, Scott A. Laurie, Sébastien J. Hotte, Simron Singh, Eric Winquist, Stephen Chia, Eric Xueyu Chen, Kelvin Chan, Patricia A. English, Ian W. Taylor, Susan Quinn, C. Mormont, Denis Soulières	5
7	A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck 2012 ·Annals of Oncology ·A.R. Abdul Razak, Denis Soulières, Scott A. Laurie, Sébastien J. Hotte, Shripriya Singh, Eric Winquist, Stephen Chia, Christophe Le Tourneau, (unknown), (unknown), Kelvin Chan, (unknown), Nagdeep Giri, C. Mormont, Susan Quinn, Lillian L. Siu	82
8	Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer 2010 ·Journal of Clinical Oncology ·Lecia V. Sequist, Benjamin Besse, Thomas J. Lynch, Vincent A. Miller, Kwok‐Kin Wong, Barbara J. Gitlitz, Keith D. Eaton, Charles Zacharchuk, Amy Freyman, Christine Powell, Revathi Ananthakrishnan, Susan Quinn, Jean‐Charles Soria	357
9	A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors 2009 ·Clinical Cancer Research ·(unknown), Paula M. Fracasso, Ronald M. Bukowski, Thomas J. Lynch, Pamela N. Münster, Geoffrey I. Shapiro, Pasi A. Jänne, Joseph P. Eder, Michael Naughton, Matthew J. Ellis, Suzanne F. Jones, Tarek Mekhail, Charles Zacharchuk, Jennifer Vermette, Richat Abbas, Susan Quinn, Christine Powell, Howard A. Burris	240
10	Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer 2008 ·Clinical Cancer Research ·Gunnar Folprecht, Josep Tabernero, Claus‐Henning Köhne, Charles Zacharchuk, Luis Paz‐Ares, Federico Rojo, Susan Quinn, (unknown), Ramón Salazar, Richat Abbas, (unknown), (unknown), Jordi Andreu, (unknown), H. Cortés-Funes, José Baselga	17
11	203 POSTER Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer 2008 ·European Journal of Cancer Supplements ·Benjamin Besse, Keith D. Eaton, J.C. Soria, Timothy Lynch, V.A. Miller, Kwok‐Kin Wong, Charles S. Powell, Susan Quinn, Charles Zacharchuk, Lecia V. Sequist	14
12	Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors 2006 ·Journal of Clinical Oncology ·Charles Erlichman, Manuel Hidalgo, Joseph Boni, Patrícia Rocha Martins, Susan Quinn, Charles Zacharchuk, (unknown), Alex A. Adjei, Eric K. Rowinsky	109
13	Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC) 2004 ·Journal of Clinical Oncology ·Sabine Tejpar, Eric Van Cutsem, Érick Gamelin, D. Machover, P Soulié, Ayhan Ulusakarya, (unknown), (unknown), Susan Quinn, Charles Zacharchuk	10
14	Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC) 2004 ·Journal of Clinical Oncology ·Sabine Tejpar, Eric Van Cutsem, Érick Gamelin, D. Machover, P Soulié, Ayhan Ulusakarya, (unknown), (unknown), Susan Quinn, Charles Zacharchuk	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact